Most Read Articles
Natalia Reoutova, 2 days ago

Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of 60 percent in pretreated and treatment-naïve RET-mutated (RETmut) medullary thyroid cancer (MTC) patients.

Carbon monoxide may have potent anti-breast cancer effects

29 Nov 2020
Researchers hypothesise that carbon monoxide in low doses may have a role to play in medicine

Women who have a history of carbon monoxide poisoning (COP) appear to be at a lower risk of developing breast cancer, a recent Taiwan study has found. This points to a potential protective effect of CO against breast cancer.

Drawing from the Nationwide Poisoning Database of Taiwan, the researchers identified 7,053 women who had been diagnosed with COP between 2002 and 2009. Participants were followed until the end of 2014, after which the risk of developing breast cancer was calculated. Non-poisoning controls (n=42,318) were extracted from the National Health Insurance Research Database.

Over the follow-up period, the incidence rate of breast cancer was significantly lower in the COP cohort than in the controls (0.7 percent vs 1.0 percent; p<0.001), but no significant difference in the age at breast cancer diagnosis was reported.

Cox proportional hazards regression confirmed this initial finding. A COP diagnosis reduced the likelihood of being diagnosed with breast cancer by more than 30 percent (hazard ratio [HR], 0.67, 95 percent confidence interval [CI], 0.50–0.91; p=0.009). This protective effect persisted even after controlling for confounders.

Stratifying according to follow-up duration showed that the effect of COP was stronger during the first year of follow-up, cutting the risk of breast cancer nearly by half. Nevertheless, the risk of breast cancer remained significantly attenuated even beyond the 1-year mark.

The researchers explained that such an anti-breast cancer action “may be attributed to the direct and indirect inhibitory effects of CO on tumour growth.”

“Further studies involving collection of complete variables for possible confounders in the patients with breast cancer as well as animal and laboratory trial experiments on the mechanisms are warranted,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 2 days ago

Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of 60 percent in pretreated and treatment-naïve RET-mutated (RETmut) medullary thyroid cancer (MTC) patients.